A Phase 1, Open Label, Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MG1102 in Patients with Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs MG 1102 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors GC Pharma
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 28 Mar 2017 Status changed from discontinued to completed, according to the results published in the Investigational New Drugs
- 28 Mar 2017 Results published in the Investigational New Drugs